Articles published by Sound Pharmaceuticals

Sound Pharmaceuticals Receives FDA Breakthrough Therapy Designation for SPI-1005 to Treat Meniere’s Disease

December 01, 2025

From Sound Pharmaceuticals

Via Business Wire

Sound Pharma to Present at Upcoming Life Sciences Industry Conferences

July 08, 2025

From Sound Pharmaceuticals

Via Business Wire

Sound Pharma to Present at Upcoming Life Science Investor Conferences

April 08, 2025

From Sound Pharmaceuticals

Via Business Wire

Sound Pharma to Present SPI-1005 Preclinical and Clinical Hearing Loss and Tinnitus Data at the Defense Health Agency Hearing Center of Excellence Symposia and ARO MWM

February 18, 2025

From Sound Pharmaceuticals

Via Business Wire

Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005

December 10, 2024

From Sound Pharmaceuticals

Via Business Wire

Sound Pharma Announces Phase 3 Study Completion of SPI-1005 for the Treatment of Meniere’s Disease

July 31, 2024

From Sound Pharmaceuticals

Via Business Wire

Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA

May 20, 2024

From Sound Pharmaceuticals

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.